Barely Significant
← all excerpts

The efficacy and safety of tislelizumab in the treatment of locally advanced or metastatic lung cancer: a systematic review and meta-analysis.

Front Pharmacol · 2025 · PMC12602520 · PMID 41230094

2
hedged sentences
closest p
boldest claim

The sentences

Furthermore, heterogeneity tests for the differences in effect sizes between these subgroups did not reach statistical significance, findings that align with those reported by Ul et al.

also in 111,027 other papers

a positive trendno p-value reported
Similarly, the lack of a statistically significant improvement in OS and PFS in our RCT analysis, despite a positive trend, echoes the nuanced results seen in some earlier meta-analyses of immunotherapy, where benefits were sometimes confined to specific subgroups or required longer follow-up to become apparent ( Chen et al., 2018 ; Peng and Wu, 2019 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.